Galderma Group AG
Restylane Defyne for Correction of Chin Retrusion
- Conditions
- Chin Retrusion
- Interventions
- Device: Restylane Defyne
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 148
- Registration Number
- NCT03597256
- Locations
- 🇨🇳
Galderma Research Site, Shanghai, Shanghai, China
PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK
- Conditions
- Actinic Keratoses
- Interventions
- Drug: Methyl Aminolaevulinate 16% Cream
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT03511326
- Locations
- 🇩🇪
University Hospital Regensburg, Regensburg, Germany
New Dermal Filler for Lip Augmentation
- Conditions
- Lip Augmentation
- Interventions
- Device: New Dermal Filler
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 273
- Registration Number
- NCT03320824
- Locations
- 🇺🇸
Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta, Georgia, United States
🇺🇸Maryland Dermatology, Laser, Skin & Vein Institute, Hunt Valley, Maryland, United States
🇺🇸BOYD, Birmingham, Michigan, United States
A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
- Conditions
- Nasolabial FoldSafety
- Interventions
- Device: ComparatorDevice: GP0045
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT03300466
- Locations
- 🇸🇪
Q-Med, Uppsala, Sweden
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- Drug: CD11301 0.03%Drug: PlaceboDrug: CD11301 0.06%
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 86
- Registration Number
- NCT03292406
- Locations
- 🇩🇪
Galderma Investigational Site, Berlin, Germany
Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
- Conditions
- Midface Volume Deficit
- Interventions
- Device: Restylane Volyme
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 168
- Registration Number
- NCT03289052
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: PlaceboDrug: CD5024 0.3% cream
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 63
- Registration Number
- NCT03250624
- Locations
- 🇨🇦
Galderma Investigational Site (#8089), Montreal, Quebec, Canada
🇨🇦Galderma Investigational Site (# 8060), Windsor, Ontario, Canada
🇨🇦Galderma Investigational Site (#8581), Mississauga, Ontario, Canada
Safety and Efficacy of Nemolizumab in PN
- Conditions
- Prurigo Nodularis
- Interventions
- Drug: CD14152 placeboDrug: CD14152 Dose A
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT03181503
- Locations
- 🇩🇪
Unikl. Schleswig-Holstein - Lübeck, Lubeck, Germany
🇵🇱Dermoklinika Centrum Medyczne s.c. M.Kierstan, J.Narbutt, A.Lesiak, Łódź, Poland
🇵🇱Kliniczny Szpital Wojew. nr 1 im. F.Chopina w Rzeszowie, Rzeszów, Poland
Pain and Safety of Restylane Perlane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
- Conditions
- Nasolabial Fold
- Interventions
- Device: Restylane Perlane LidocaineDevice: Restylane Perlane
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT03174132
- Locations
- 🇨🇳
Kaohsiung Medical University, Kaohsiung, Taiwan
🇨🇳Chang Gung Memorial Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
- Conditions
- Cheek AugmentationMidface Contour Deficiencies
- Interventions
- Device: Restylane Lyft with Lidocaine
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT03160716
- Locations
- 🇺🇸
Union Square Laser Dermatology, New York, New York, United States
🇺🇸Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States
🇺🇸Facial Plastic and Cosmetic Surgery, Beverly Hills, California, United States